SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences today announced that company management will participate at the following virtual investor conferences:
-
Stifel 2021 Virtual Healthcare Conference
Formal presentation on Tuesday, November 16, 2021 at 11:00 a.m. PT / 2:00 p.m. ET -
Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum
Fireside chat on Thursday, November 18, 2021 at 1:00 p.m. PT / 4:00 p.m. ET
A live webcast of the Stifel event will be available on the “For Investors” section of the InterVenn website at https://intervenn.com/investors/ and will be available for 90 days thereafter.
About InterVenn Biosciences
InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the PerspectIV™ suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. For more information about InterVenn Biosciences, please visit the company’s website.
